grant
Project 2
Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 15 Sept 2019Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY20254 repeats tau4R tauAccountingAlzheimer beta-ProteinAlzheimer's Amyloid beta-ProteinAlzheimer's amyloidAmentiaAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid Protein A4Amyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinAndroid AppAndroid ApplicationAssessment instrumentAssessment toolAstroproteinAutopsyAβBiologic ModelsBiologicalBiological MarkersBiological ModelsBlood PlasmaC9ORF72Care GiversCaregiversCell Phone ApplicationCell phone AppCellular Phone AppCellular Phone ApplicationClinicalClinical TrialsClinical dementia rating scaleDataData CollectionDecentralizationDementiaDementia rating scaleDiagnosisDiseaseDisease ProgressionDisorderEarly DiagnosisEquilibriumFTD TDPFTD TDP43FTLDFTLD TDPFTLD TDP43FTLD TDP43 proteinopathyFingersFrontal Temporal Lobar DegenerationFrontotemporal Lobar DegenerationsFrontotemporal variety lobar degenerationFutureGFA-ProteinGFAPGaitGeneticGeographyGlial Fibrillary Acid ProteinGlial Fibrillary Acidic ProteinGlial Intermediate Filament ProteinGoalsHomeImpairmentLaboratoriesLanguageLifeLightLiquid substanceMT-bound tauMeasuresMesulam SyndromeModel SystemModelingMonitorMotorMovementNeuropsychologic TestsNeuropsychological TestsOutcomePETPET ScanPET imagingPETSCANPETTParticipantPathologicPathologyPatientsPersonsPhonePhotoradiationPlasmaPlasma SerumPopulationPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPrimary Progressive AphasiaProgram DevelopmentProgressive Supranuclear OphthalmoplegiaProgressive Supranuclear PalsyProteinsProteomicsQuestionnairesR-Series Research ProjectsR01 MechanismR01 ProgramRad.-PETReportingResearchResearch GrantsResearch Project GrantsResearch ProjectsReticuloendothelial System, Serum, PlasmaSOD-1SOD-1 proteinSOD1SOD1 geneSOD1 gene productSample SizeSelf AdministeredSelf AdministrationSemanticsSeverity of illnessSmart Phone AppSmart Phone ApplicationSmartphone AppSpeechSteele-Richardson-Olszewski DiseaseSteele-Richardson-Olszewski SyndromeSumSyndromeSystemTAR DNA binding protein 43 kDa pathologyTAR DNA binding protein 43 pathologyTAR DNA binding protein of 43 proteinopathyTAR DNA-binding protein 43TDP-43TDP43TDP43 associated neurodegenerationTDP43 associated neurodegenerative diseaseTDP43 associated pathologiesTDP43 induced neurodegenerationTDP43 neurodegenerationTDP43 neurodegenerative diseaseTDP43 neuropathologyTDP43 pathogenesisTDP43 pathologyTDP43 proteinopathyTDP43 related neurodegenerationTDP43 related pathologyTechniquesTelephoneTrans active response DNA binding protein 43 pathologyTrans active response DNA binding protein of 43 kDa proteinopathyTravelVariantVariationa beta peptideabetaamyloid betaamyloid-b proteinapp on a smartphoneapplication on a smartphoneautosomal dominant ADautosomal dominant Alzheimer's diseaseautosomal dominant mutationbalancebalance functionbasebasesbehavioral variant FTDbehavioral variant frontotemporal degenerationbehavioral variant frontotemporal dementiabeta amyloid fibrilbio-markersbiologicbiologic markerbiomarkerbiomarker developmentbiomarker discoverybiomedical referral centerbody movementbvFTDcandidate biomarkercandidate markercell phone based appchromosome 9 open reading frame 72clinical carecognitive assessmentcognitive testingdigital assessmentdisease modeldisease severitydisorder modeldrug developmentearly detectionextracellular vesiclesfluidfour repeats taufrontotemporal lobar degeneration caused by TDP43 proteinopathyfrontotemporal lobar degeneration with TDP43 pathologyfrontotemporal lobar degeneration with TDP43 proteinopathyhomesiOS appiOS applicationiPhone AppiPhone Applicationimprovedliquidmicrotubule bound taumicrotubule-bound taumobile phone appmolecular pathologymulti-modalitymultimodalitymutation carriernecropsyneurofilamentnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyphone appphone applicationpositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypostmortempre-clinicalpreclinicalprotein TDP-43protein TDP43recruitreferral centersmartphone applicationsmartphone based appsmartphone based applicationsoluble amyloid precursor proteinsuccesssuperoxide dismutase 1targeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttautau Proteinstau factortooltrans active response DNA binding protein 43 kDa pathologytrans active response DNA binding protein 43 proteinopathyτ Proteins
Description preview
ABSTRACT – ALLFTD2: PROJECT 2
Approximately 70% of FTLD cases are sporadic (s-FTLD) and have no clear genetic or other identifiable cause.
Like familial FTLD (f-FTLD), s-FTLD is uniformly fatal and there are no approved treatments. The most common
s-FTLD syndrome is sporadic behavioral variant frontotemporal dementia (s-bvFTD), accounting for at…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click